Keywords: biologics, efalizumab, psoriasis, T-cell, T-cell activation, recirculation. Thus, LFA-1 is likely to be involved in numerous crucial steps of the pathogenesis of psoriasis, namely activation of T-cells in lymph nodes upon encounter of antigen transported there by dendritic cells of the epidermis, extravazation of circulating T-cells in inflammatory skin, T-cell re-activation in the skin by antigen-presenting cells, and keratinocyte interaction with infiltrating activated T-cells. Keywords: Efalizumab, Nail, Palmoplantar, Psoriasis, Scalp. At the time this study was completed, efalizumab was approved for the treatment of adults with moderate-to-severe, chronic plaque psoriasis. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Acute episodes of plaque psoriasis may evolve into more severe disease – eg, pustular or erythrodermic psoriasis. Etanercept and efalizumab for the treatment of adults with psoriasis; NICE Technology Appraisal Guidance, July 2006. You’re not alone, reach out to thousands of patients. The clinical type of psoriasis and severity of the disease should be established early to guide treatment.
61 Efalizumab for the treatment of moderate to severe plaque psoriasis. Successful management and re-treatment. Guttate psoriasis is characterized by the acute onset of small, 1-10 mm diameter, droplike, erythematous-to-salmon-pink papules, usually with a fine scale, as demonstrated in the images below. The word guttate is derived from the Latin word gutta, meaning drop. Balato A, La Bella S, Gaudiello F, Balato N. Efalizumab-induced guttate psoriasis. A new self-injected medication called efalizumab (Raptiva) has the potential to be effective for severe cases of psoriasis. KEY TERMS.
Long-term Treatment Of Plaque Psoriasis With Efalizumab: An Italian Experience
Key Words: Hand and foot, psoriasis, efalizumab, monoclonal antibody. The safety and efficacy of efalizumab for the treatment of moderate-to-severe plaque psoriasis have been well documented in multiple, phase III, randomized, placebocontrolled, multicenter studies.